SMTL ID : 8bsk.1

Human GLS in complex with compound 3

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.10 Å

Oligo State

homo-tetramer

Ligands

36 x SO4: SULFATE ION(Non-functional Binders)

SO4.1: 3 residues within 4Å: Chain A: V.116, N.117, R.169 Ligand excluded by PLIP SO4.2: 3 residues within 4Å: Chain A: F.155, N.157, A.158 Ligand excluded by PLIP SO4.3: 4 residues within 4Å: Chain A: Y.176, K.180 Chain B: K.102, R.169 Ligand excluded by PLIP SO4.4: 3 residues within 4Å: Chain A: F.160, Q.161, R.164 Ligand excluded by PLIP SO4.5: 3 residues within 4Å: Chain A: Y.90, P.184, E.185 Ligand excluded by PLIP SO4.6: 6 residues within 4Å: Chain A: R.164, E.165, D.168, F.171 Chain B: Y.175, K.178 Ligand excluded by PLIP SO4.7: 8 residues within 4Å: Chain A: Y.31, Q.67, S.68, N.117, E.163, N.170, Y.196, C.200 Ligand excluded by PLIP SO4.8: 9 residues within 4Å: Chain A: P.95, S.96, N.113, V.116, S.244, C.245, Y.248, D.249, S.251 Ligand excluded by PLIP SO4.9: 3 residues within 4Å: Chain A: F.137, F.155, Q.198 Ligand excluded by PLIP SO4.11: 3 residues within 4Å: Chain B: V.116, N.117, R.169 Ligand excluded by PLIP SO4.12: 3 residues within 4Å: Chain B: F.155, N.157, A.158 Ligand excluded by PLIP SO4.13: 4 residues within 4Å: Chain A: K.102, R.169 Chain B: Y.176, K.180 Ligand excluded by PLIP SO4.14: 3 residues within 4Å: Chain B: F.160, Q.161, R.164 Ligand excluded by PLIP SO4.15: 3 residues within 4Å: Chain B: Y.90, P.184, E.185 Ligand excluded by PLIP SO4.16: 6 residues within 4Å: Chain A: Y.175, K.178 Chain B: R.164, E.165, D.168, F.171 Ligand excluded by PLIP SO4.17: 8 residues within 4Å: Chain B: Y.31, Q.67, S.68, N.117, E.163, N.170, Y.196, C.200 Ligand excluded by PLIP SO4.18: 9 residues within 4Å: Chain B: P.95, S.96, N.113, V.116, S.244, C.245, Y.248, D.249, S.251 Ligand excluded by PLIP SO4.19: 3 residues within 4Å: Chain B: F.137, F.155, Q.198 Ligand excluded by PLIP SO4.21: 3 residues within 4Å: Chain C: V.116, N.117, R.169 Ligand excluded by PLIP SO4.22: 3 residues within 4Å: Chain C: F.155, N.157, A.158 Ligand excluded by PLIP SO4.23: 4 residues within 4Å: Chain C: Y.176, K.180 Chain D: K.102, R.169 Ligand excluded by PLIP SO4.24: 3 residues within 4Å: Chain C: F.160, Q.161, R.164 Ligand excluded by PLIP SO4.25: 3 residues within 4Å: Chain C: Y.90, P.184, E.185 Ligand excluded by PLIP SO4.26: 6 residues within 4Å: Chain C: R.164, E.165, D.168, F.171 Chain D: Y.175, K.178 Ligand excluded by PLIP SO4.27: 8 residues within 4Å: Chain C: Y.31, Q.67, S.68, N.117, E.163, N.170, Y.196, C.200 Ligand excluded by PLIP SO4.28: 9 residues within 4Å: Chain C: P.95, S.96, N.113, V.116, S.244, C.245, Y.248, D.249, S.251 Ligand excluded by PLIP SO4.29: 3 residues within 4Å: Chain C: F.137, F.155, Q.198 Ligand excluded by PLIP SO4.31: 3 residues within 4Å: Chain D: V.116, N.117, R.169 Ligand excluded by PLIP SO4.32: 3 residues within 4Å: Chain D: F.155, N.157, A.158 Ligand excluded by PLIP SO4.33: 4 residues within 4Å: Chain C: K.102, R.169 Chain D: Y.176, K.180 Ligand excluded by PLIP SO4.34: 3 residues within 4Å: Chain D: F.160, Q.161, R.164 Ligand excluded by PLIP SO4.35: 3 residues within 4Å: Chain D: Y.90, P.184, E.185 Ligand excluded by PLIP SO4.36: 6 residues within 4Å: Chain C: Y.175, K.178 Chain D: R.164, E.165, D.168, F.171 Ligand excluded by PLIP SO4.37: 8 residues within 4Å: Chain D: Y.31, Q.67, S.68, N.117, E.163, N.170, Y.196, C.200 Ligand excluded by PLIP SO4.38: 9 residues within 4Å: Chain D: P.95, S.96, N.113, V.116, S.244, C.245, Y.248, D.249, S.251 Ligand excluded by PLIP SO4.39: 3 residues within 4Å: Chain D: F.137, F.155, Q.198 Ligand excluded by PLIP

4 x 04A: N,N'-[sulfanediylbis(ethane-2,1-diyl-1,3,4-thiadiazole-5,2-diyl)]bis(2-phenylacetamide)(Non-covalent)

04A.10: 15 residues within 4Å: Chain A: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Chain B: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Ligands: 04A.20 15 PLIP interactions: 6 interactions with chain A, 9 interactions with chain B Hydrophobic interactions: A:F.104, A:E.107, A:Y.176, B:L.103, B:F.104, B:E.107, B:Y.176 Hydrogen bonds: A:F.104, A:L.105, A:L.105, B:F.104, B:L.105, B:L.105 Water bridges: B:Y.176, B:Y.176 04A.20: 15 residues within 4Å: Chain A: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Chain B: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Ligands: 04A.10 15 PLIP interactions: 7 interactions with chain A, 8 interactions with chain B Hydrophobic interactions: A:L.103, A:F.104, A:E.107, A:Y.176, B:F.104, B:E.107, B:Y.176 Hydrogen bonds: A:F.104, A:L.105, A:L.105, B:F.104, B:L.105, B:L.105 Water bridges: B:Y.176, B:Y.176 04A.30: 15 residues within 4Å: Chain C: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Chain D: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Ligands: 04A.40 15 PLIP interactions: 6 interactions with chain C, 9 interactions with chain D Hydrophobic interactions: C:F.104, C:E.107, C:Y.176, D:L.103, D:F.104, D:E.107, D:Y.176 Hydrogen bonds: C:F.104, C:L.105, C:L.105, D:F.104, D:L.105, D:L.105 Water bridges: D:Y.176, D:Y.176 04A.40: 15 residues within 4Å: Chain C: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Chain D: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Ligands: 04A.30 15 PLIP interactions: 7 interactions with chain C, 8 interactions with chain D Hydrophobic interactions: C:L.103, C:F.104, C:E.107, C:Y.176, D:F.104, D:E.107, D:Y.176 Hydrogen bonds: C:F.104, C:L.105, C:L.105, D:F.104, D:L.105, D:L.105 Water bridges: D:Y.176, D:Y.176

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Finlay, M.R.V. et al., Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. J Med Chem (2019)

Release Date

2023-01-18

Peptides

Glutaminase kidney isoform, mitochondrial 65 kDa chain: ABCD

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
A

C
A

D
A

Glutaminase kidney isoform, mitochondrial 65 kDa chain

Related Entries With Identical Sequence